CSI Market
Sign In | Register

Apogee Therapeutics Inc (APGE) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access APGE quarterly Cash Flow →
Cash flow data covering Apogee Therapeutics Inc– offers a view into how Dec 31 2025's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023)
Operating Activities
Income-255.84
Depreciation & amortization1.42
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation46.28
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Investment Income Amortization Of Discount-7.50
Operating Lease Expense-
Increase Decrease In Operating Lease Liability-3.98
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable0.15
Increase (Decrease) in Accrued Liabilities-1.07
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expenses, Other-2.11
Other Working Capital-8.47
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities3.68
Discontinued operations0.00
Net Cash flow from Operating Activities-227.45
Investing Activities
Capital Expenditures-5.15
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities467.87
Payments to Acquire Marketable Securities-642.30
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-179.57
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net388.64
Unpaid Financing Cost In Accrued Liability-
Deferred Financing Issuance Costs In Accrued Liability-
Deferred Financing Issuance Costs In Accounts Payable-
Proceeds From Exercise Of Options And Employee Stock Purchase Plan Purchases6.86
Stock Issued-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability1.00
Deferred Financing Issuance Costs In Accounts Payable And Accrued Expenses-
Capital Expenditures Incurred But Not Yet Paid-
Proceeds From Issuance Of Common Stock Under The At The Market Net Of Issuance Costs-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities396.49
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-232.60
Total Cash Flow-10.53
4 historic quarters locked

Sign in to unlock the full Apogee Therapeutics Inc cash flow history.

Sign In Create Free Account

About Apogee Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001974640-26-000002

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License